Wall Street brokerages predict that Cardlytics, Inc. (NASDAQ:CDLX – Get Rating) will announce sales of $77.11 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Cardlytics’ earnings, with estimates ranging from $76.62 million to $77.60 million. Cardlytics reported sales of $58.85 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 31%. The business is expected to report its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Cardlytics will report full year sales of $351.25 million for the current fiscal year, with estimates ranging from $351.10 million to $351.39 million. For the next fiscal year, analysts expect that the company will post sales of $455.41 million, with estimates ranging from $452.10 million to $458.71 million. Zacks’ sales averages are an average based on a survey of research firms that cover Cardlytics.
Cardlytics (NASDAQ:CDLX – Get Rating) last posted its quarterly earnings results on Monday, May 2nd. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.36. Cardlytics had a negative return on equity of 13.81% and a negative net margin of 25.06%. The business had revenue of $67.93 million during the quarter, compared to the consensus estimate of $65.84 million. During the same quarter in the previous year, the firm earned ($0.59) earnings per share.
NASDAQ CDLX opened at $29.05 on Tuesday. The firm has a market capitalization of $991.04 million, a P/E ratio of -12.97 and a beta of 2.47. The business has a fifty day simple moving average of $43.79 and a 200 day simple moving average of $58.07. Cardlytics has a 12 month low of $27.57 and a 12 month high of $134.91. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.32.
In other news, Director Scott D. Grimes sold 4,098 shares of the business’s stock in a transaction that occurred on Tuesday, April 19th. The stock was sold at an average price of $50.09, for a total transaction of $205,268.82. Following the transaction, the director now directly owns 243,606 shares of the company’s stock, valued at $12,202,224.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Scott D. Grimes sold 6,000 shares of Cardlytics stock in a transaction that occurred on Thursday, March 3rd. The shares were sold at an average price of $58.28, for a total value of $349,680.00. The disclosure for this sale can be found here. Insiders sold a total of 52,050 shares of company stock worth $2,118,480 over the last ninety days. Insiders own 3.70% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. CAS Investment Partners LLC increased its position in Cardlytics by 0.7% in the fourth quarter. CAS Investment Partners LLC now owns 5,186,466 shares of the company’s stock worth $342,774,000 after buying an additional 36,875 shares in the last quarter. FMR LLC boosted its stake in Cardlytics by 2.3% during the first quarter. FMR LLC now owns 3,284,572 shares of the company’s stock valued at $54,327,000 after buying an additional 72,847 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Cardlytics by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 2,928,435 shares of the company’s stock valued at $161,005,000 after purchasing an additional 23,393 shares during the last quarter. KPS Global Asset Management UK Ltd lifted its stake in shares of Cardlytics by 5.9% in the 4th quarter. KPS Global Asset Management UK Ltd now owns 1,246,830 shares of the company’s stock valued at $82,403,000 after purchasing an additional 70,000 shares during the last quarter. Finally, Baillie Gifford & Co. raised its holdings in shares of Cardlytics by 15.1% in the first quarter. Baillie Gifford & Co. now owns 1,056,208 shares of the company’s stock worth $58,071,000 after buying an additional 138,332 shares during the period. Hedge funds and other institutional investors own 97.57% of the company’s stock.
About Cardlytics (Get Rating)
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
- Get a free copy of the StockNews.com research report on Cardlytics (CDLX)
- Cheap Buys: These 3 Stocks are Now Trading Under $20
- Time to Ring the Register on Funko Stock
- Stock Market Downgrades Are Dragging The S&P 500 Lower
- Palo Alto Networks Bottoms But A Rebound May Not Be Coming
- Under Armor Stock is Getting Undervalued
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.